Central nervous system (CNS) niche disorders have always been a major challenge and FS is no different. Some of the key products in late-stage clinical trials have shown considerable promise and offer high growth opportunities.
It has been suggested that tumours are derived from a small subpopulation of 'cancer stem cells'. If these stem cells are not affected by a cancer therapy the treatment is only likely to be palliative and the tumour will re-grow.
Epistem announced today that Exponential Biotherapies, Inc (EBI). of Virginia, USA, have contracted Epistem to provide their specialised preclinical efficacy testing services for agents likely to protect the gastrointestinal tract against radiation damage. The first compound that Epistem will assess
Epistem announced today that it had successfully completed a preliminary study with AstraZeneca for the use of its proprietary, minimally invasive plucked human hair biomarker technology to help steer oncology drug development. The technology includes analysing gene expression change in
TAP Pharmaceutical Products reported results from three pivotal Phase 3 studies evaluating investigational new drug TAK-390MR, the first proton pump inhibitor with an innovative dual delayed release technology, in healing patients with erosive esophagitis and in maintenance of healed EE.
assisTek, the global leader tablet ePROs, today announced the launch of their new corporate website at http://www.assistek.com. The website features a video interview of site coordinators who used assisTek systems with an elderly Spanish speaking arthritic population on the Mexican
Five Prime Therapeutics, Inc. and Pfizer Inc. (NYSE:PFE) today announced the initiation of a worldwide collaborative research and license agreement. The collaboration will focus on the discovery of antibody targets and novel therapeutic protein products to treat certain areas of
Better Packages, Inc., the number-one trusted name in water-activated paper tape dispensers and carton sealers for more than 90 years, has reinforced its commitment to providing sustainable carton sealing solutions by joining a leading professional trade association focused on sustainability--the
The Champion for Change Award is an achievement reserved for organizational partners supplying health care products and services that are considerate of the earth and its resources. (PRWeb May 20, 2008) Read the full story at
The Patient Recruiting AgencyTM will begin recruiting patients with major depressive disorder for a medical research study on May 20, 2008. (PRWeb May 20, 2008) Read the full story at http://ww1.prweb.com/releases/study/patient/prweb961024.htm
A report, released jointly today by the National Association of Chain Drug Stores (NACDS) and the Food Marketing Institute (FMI), analyzes the potential impact of the DRA on pharmacies (Impact of the Deficit Reduction Act of 2005 on Pharmacies by
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that Nexavar tablets significantly improved overall survival by 47.3% in patients in the Asia-Pacific region with advanced hepatocellular carcinoma, or primary liver cancer compared to those receiving placebo.
Pulmo BioTech has reported details of the methodology and purpose of its Phase I human trials with its PulmoBind molecular imaging technology for the diagnosis of pulmonary embolism and pulmonary hypertension.
Salix Pharmaceuticals has received an approvable letter from the FDA for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older.
Phenomix has announced that PHX1149, a dipeptidyl peptidase-4 inhibitor, demonstrated positive results in a Phase IIb clinical trial for the treatment of Type 2 diabetes.
Veridex has announced that its licensing collaborator, Laboratory Corporation of America Holdings, has launched a new gene methylation test for prostate cancer.
Pharmaxis, a pharmaceutical company committed to the research, development and commercialization of human therapeutic products, has received national approval to market Aridol in Germany.
Tap Pharmaceutical Products has reported promising results from three pivotal Phase III studies evaluating investigational new drug TAK-390MR, the first proton pump inhibitor with a dual delayed release technology, in healing patients with erosive esophagitis and in maintenance of healed
GlaxoSmithKline has reported that the use of its Advair Diskus 250/50 demonstrated a 30% reduction in exacerbations in patients with chronic obstructive pulmonary disease who have a history of exacerbations as compared with salmeterol alone.
